CJC-1295 (no DAC) + Ipamorelin — Research Overview

Research Overview

This catalog combination brings together a GHRH-related peptide designated “No DAC” and ipamorelin, a growth-hormone secretagogue. The distinction between the exact combination and separately studied compounds is central to interpreting the evidence. [1][2][3][4]

What the Compound Is

“CJC-1295 No DAC” is a commercial designation for a short-acting GHRH analog. The long-acting, albumin-binding CJC-1295 used in prominent clinical publications is a different formulation. Ipamorelin has been studied separately as a secretagogue. [1][2][3]

Regulatory or Investigational Status

The catalog combination is not an FDA-approved medicine. Regulatory discussions of CJC-1295 and ipamorelin also identify characterization and safety-data limitations; they do not establish authorization for this mixture. [4]

Mechanisms or Pathways Under Investigation

GHRH-receptor and ghrelin-receptor signaling can influence endogenous GH release, with downstream IGF-1 responses. Complementary receptor activity is a rationale for study, not evidence that this exact combination improves body composition, recovery or sleep. [1][2][3]

Major Research Context

Human CJC-1295 research investigated GH and IGF-1 responses and secretion patterns with the long-acting molecule. Human ipamorelin research examined pharmacokinetics and GH responses independently. Neither establishes outcomes for the No DAC combination. [1][2][3]

Published Research Highlights

Human study · Long-acting CJC-1295

Teichman and colleagues observed prolonged GH and IGF-1 responses. The albumin-binding compound studied should not be represented as the No DAC product. [1]

Human mechanistic study · GH pulsatility

Ionescu and colleagues examined pulsatile GH release during long-acting CJC-1295 exposure. [2]

Human pharmacology · Ipamorelin alone

Gobburu and colleagues modeled ipamorelin exposure and GH response in volunteers; this was not a trial of the combined formulation. [3]

Evidence Level and Research Limitations

Endocrine biomarker changes do not demonstrate clinical benefit. No direct controlled trial of the exact catalog blend is established by the sources below. Product identity, duration and study population prevent assuming interchangeability. [1][2][3][4]

Selected Scientific References

Teichman et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. JCEM, 2006. ↗Human study · Long-acting DAC compound
Ionescu et al. Pulsatile secretion of GH persists during stimulation by CJC-1295. JCEM, 2006. ↗Human mechanistic study · DAC compound
Gobburu et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharmaceutical Research, 1999. ↗Human pharmacology · Ipamorelin alone
FDA. Safety and characterization considerations for selected peptide substances. ↗Official regulatory material

Educational and Research Disclaimer

This page is for educational and scientific-reference purposes. It does not provide medical advice, diagnosis, treatment recommendations, dosing guidance or instructions for human use. References concern the specific materials and conditions studied; they are not evidence that an AUVYRON product has been evaluated in those studies. Product presentations are catalog identifiers, not use instructions.

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.